Disclaimer: You are now leaving www.HIVReagentProgram.org and are going to a website that is not operated by NIH HIV Reagent Program. We are not responsible for the content or availability of linked sites.
ABOUT THIRD PARTY LINKS ON OUR SITE: NIH HIV Reagent Program offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet. When you click on these links, you will leave the NIH HIV Reagent Program website and will be redirected to another site. These sites are not under the control of NIH HIV Reagent Program. NIH HIV Reagent Program is not responsible for the content of linked third party websites. We are neither an agent for these third parties nor do we endorse or guarantee their products. We make no representation or warranty regarding the accuracy of the information contained in the linked sites. We suggest that you always verify the information obtained from linked websites before acting upon this information. Please read third party privacy and security policies closely as these may be different than NIH HIV Reagent Program policies. If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly.
Room temperature, protected from moisture
ARP-4101(pNL-r-HSAS) is a HIV-1-based reporter vector that is both replication-competent and pathogenic in vivo. Virus produced from pNL-r-HSAS infects cells expressing both CD4 and CXCR4. Infected cells express surface heat stable antigen (HAS) which is detectable by flow cytometry.
pNL-r-HSAS contains a 267 base pair fragment from the ORF of HSA that was inserted into an introduced XbaI site (nt 5625) and an existing EcoRI site (nt 5743) of cloning vector pNL4-3. This site is within the NL4-3 vpr gene, which was paritally deleted during the digests. In addition, the start of vpr and two potential start sites in the 3' end of vif are silenced by site-specific mutagenesis. The insert was cloned in the 5'-3' orientation. The murine HSA insert was derived from the plasmid pSL87c4-1. The insert contains the HSA ORF and 36 extraneous bases from the original plasmid. HSA expression is driven by the HIV-1 long terminal repeat (LTR).For additional details please refer to the provided plasmid map and sequence file.
Each vial of ARP-4101 contains approximately 2.45 µg of dried purified DNA stabilized in DNAstable®PLUS. Please refer to the appropriate data sheet for lot-specific information.
Jamieson, B. D. and J. A. Zack. “In Vivo Pathogenesis of a Human Immunodeficiency Virus Type 1 Reporter Virus.” J Virol. 72 (1998): 6520-6526. PubMed:9658095.
Adachi, A., et al. “Production of Acquired Immunodeficiency Syndrome-Associated Retrovirus in Human and Nonhuman Cells Transfected with an Infectious Molecular Clone.” J Virol.59 (1986): 284-291. PubMed:3016298.
Kay, R., F. Takei and R. K. Humphries. “Expression Cloning of a cDNA Encoding MI/J11d Heat-Stable Antigens.” J Immunol. 14 (1990): 1952-1959. PubMed: 2118158.
When applying for permits and forms please:
Do NOT reference NIH HIV Reagent Program or ATCC Catalog Numbers in the Material Description fields found on the permits and/or forms.
Make sure your name and address on the permit applications and/or forms are exactly as they appear on your NIH HIV Reagent Program registration.
Information about permits is provided as a courtesy to NIH HIV Reagent Program customers. While we use reasonable efforts to include accurate and up-to-date information on this page, we make no warranties or representation as to its accuracy.
For more information on the necessary compliance requirements associated with the biological materials provided by NIH HIV Reagent Program, please select this link: Compliance Requirements.